Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer

被引:0
作者
Shore, Neal [1 ]
Carles, Joan [2 ]
McDermott, Ray [3 ]
Agarwal, Neeraj [4 ]
Tombal, Bertrand [5 ]
机构
[1] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[3] St Vincents Univ Hosp, Canc Trials Ireland, Dublin, Ireland
[4] Univ Utah, Huntsman Canc Inst NCI CCC, Salt Lake City, UT USA
[5] Clin Univ St Luc, Brussels, Belgium
关键词
radium-223; metastatic castration-resistant prostate cancer; enzalutamide; treatment intensification; combination therapy; SKELETAL-RELATED EVENTS; ABIRATERONE ACETATE; DNA-REPAIR; OPEN-LABEL; SURVIVAL; THERAPY; DICHLORIDE; OUTCOMES; SAFETY; MEN;
D O I
10.3389/fmed.2024.1460212
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several life-prolonging therapies with diverse mechanisms of action (MoA) are available for the treatment of metastatic hormone-sensitive/castration-resistant prostate cancer, with many patients requiring multiple lines of therapy. Nevertheless, treatment optimization to further delay disease progression and improve overall survival remains an unmet need. Despite the number of agents with differing MoAs approved for advanced prostate cancer, many patients receive only one or two life-prolonging therapies. One strategy for enhancing the benefit of treatment for this aggressive disease is combining therapies with different MoAs (treatment intensification) early in the disease course, which may be more effective than administering therapies sequentially, yet still allow for subsequent sequential use of individual therapies to optimize patient outcomes. In this narrative review we discuss the rationale for combining 223radium dichloride (223Ra; an alpha-emitting radionuclide) with enzalutamide (an androgen receptor inhibitor) for treatment intensification, including their differing MoAs, their individual efficacy in this setting, and their largely non-overlapping tolerability profiles. We also summarize the preclinical and clinical data available for this combination to date, including interim safety data from the phase 3 EORTC 1333/PEACE III study which highlight the low fracture risk of 223Ra plus enzalutamide when administered concomitantly with bone health agents. Relevant data were sourced from clinical studies published by the authors and via searches of PubMed, clinical trial registries and congress abstracts.
引用
收藏
页数:9
相关论文
共 95 条
[1]  
accessdata, Lynparza Prescribing Information
[2]   Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer [J].
Agarwal, Neeraj ;
Nussenzveig, Roberto ;
Hahn, Andrew W. ;
Hoffman, John M. ;
Morton, Kathryn ;
Gupta, Sumati ;
Batten, Julia ;
Thorley, Jared ;
Hawks, Josiah ;
Sacristan Santos, Victor ;
Nachaegari, Gayatri ;
Wang, Xuechen ;
Boucher, Kenneth ;
Haaland, Benjamin ;
Maughan, Benjamin L. .
CLINICAL CANCER RESEARCH, 2020, 26 (09) :2104-2110
[3]   Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer [J].
Al-Ubaidi, Firas L. T. ;
Schultz, Niklas ;
Loseva, Olga ;
Egevad, Lars ;
Granfors, Torvald ;
Helleday, Thomas .
CLINICAL CANCER RESEARCH, 2013, 19 (06) :1547-1556
[4]  
[Anonymous], NCCN CLIN PRACTICE G
[5]   Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial [J].
Armstrong, Andrew J. ;
Lin, Ping ;
Tombal, Bertrand ;
Saad, Fred ;
Higano, Celestia S. ;
Joshua, Anthony M. ;
Parli, Teresa ;
Rosbrook, Brad ;
van Os, Steve ;
Beer, Tomasz M. .
EUROPEAN UROLOGY, 2020, 78 (03) :347-357
[6]   ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer [J].
Armstrong, Andrew J. ;
Szmulewitz, Russell Z. ;
Petrylak, Daniel P. ;
Holzbeierlein, Jeffrey ;
Villers, Arnauld ;
Azad, Arun ;
Alcaraz, Antonio ;
Alekseev, Boris ;
Iguchi, Taro ;
Shore, Neal D. ;
Rosbrook, Brad ;
Sugg, Jennifer ;
Baron, Benoit ;
Chen, Lucy ;
Stenzl, Arnulf .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) :2974-+
[7]   Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer [J].
Asim, Mohammad ;
Tarish, Firas ;
Zecchini, Heather I. ;
Sanjiv, Kumar ;
Gelali, Eleni ;
Massie, Charles E. ;
Baridi, Ajoeb ;
Warren, Anne Y. ;
Zhao, Wanfeng ;
Ogris, Christoph ;
McDuffus, Leigh-Anne ;
Mascalchi, Patrice ;
Shaw, Greg ;
Dev, Harveer ;
Wadhwa, Karan ;
Wijnhoven, Paul ;
Forment, Josep V. ;
Lyons, Scott R. ;
Lynch, Andy G. ;
O'Neill, Cormac ;
Zecchini, Vincent R. ;
Rennie, Paul S. ;
Baniahmad, Aria ;
Tavare, Simon ;
Mills, Ian G. ;
Galanty, Yaron ;
Crosetto, Nicola ;
Schultz, Niklas ;
Neal, David ;
Helleday, Thomas .
NATURE COMMUNICATIONS, 2017, 8
[8]   Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY [J].
Beer, Tomasz M. ;
Tombal, Bertrand .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (18) :1755-1756
[9]   nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives [J].
Berruti, Alfredo ;
Bracarda, Sergio ;
Caffo, Orazio ;
Cortesi, Enrico ;
D'Angelillo, Rolando ;
Del Re, Marzia ;
Facchini, Gaetano ;
Pappagallo, Giovanni ;
Procopio, Giuseppe ;
Sabbatini, Roberto ;
Santini, Daniele .
CANCER TREATMENT REVIEWS, 2023, 115
[10]   Glucocorticoid-induced osteoporosis [J].
Briot, Karine ;
Roux, Christian .
RMD OPEN, 2015, 1 (01)